
- /
- Supported exchanges
- / US
- / DVAX.NASDAQ
Dynavax Technologies Corporation (DVAX NASDAQ) stock market data APIs
Dynavax Technologies Corporation Financial Data Overview
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Dynavax Technologies Corporation data using free add-ons & libraries
Get Dynavax Technologies Corporation Fundamental Data
Dynavax Technologies Corporation Fundamental data includes:
- Net Revenue: 295 M
- EBITDA: 3 535 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: 0.0123
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dynavax Technologies Corporation News

Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value
Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees UrgesStockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today ...


Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
Dynavax Technologies (DVAX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates...

Dynavax Technologies First Quarter 2025 Earnings: EPS Misses Expectations
Dynavax Technologies (NASDAQ:DVAX) First Quarter 2025 Results Key Financial Results Revenue: US$68.2m (up 34% from 1Q 2024). Net loss: US$96.1m (loss widened by US$87.4m from 1Q 2024). US$0.77 loss ...

Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return Urges Stockholders to Vote "FOR" All ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.